Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Mesoblast Limited (MESO) Price & Performance

Diamondback Energy IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Mesoblast Limited — how do they compare? Diamondback Energy Inc trades at $192.78 (market cap $53.67B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Diamondback Energy Inc is far larger — about 30.7× Mesoblast Limited's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Mesoblast Limited for 15 Days on average.

FANGMESO
Market Cap
$53.67B$1.75B
Volume
2,250,644239,027
Sector
EnergyHealth
52-Week High
$213.69$20.96
52-Week Low
$137.29$13.19
Typical Hold Time
69 Days15 Days
Enterprise Value
$65.83B$1.83B
Dividend Yield
2.3%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $192.30, up 4.3% today, showing strong momentum near its recent highs. The stock maintains a bullish technical outlook with solid fundamental support from growing revenue and consistent earnings beats. Recent Q2 2026 EPS of $6.48 exceeded expectations by 6.6%, while analyst consensus remains overwhelmingly positive with 90.6% buy ratings and a $231.77 price target. The company's cash flow generation remains robust with $8.76B from operations in 2025, supporting dividend payments and strategic investments.

FANG presents a compelling growth opportunity with strong Permian Basin positioning and improving operational efficiency, though investors should monitor oil price volatility and recent insider selling activity. The stock's current valuation at 36.5x P/E reflects growth expectations, while technical indicators suggest potential resistance near $195-$197 levels. With solid institutional support and positive industry outlook, FANG remains well-positioned for continued upside if execution remains strong.

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FANG
100% Buy0% Sell
Avg holding period · 69 Days
MESO

No sentiment data available yet.

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →